Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Open-Label Extension Study to Assess the Safety and Efficacy of ARD-101 in Patients With Prader-Willi Syndrome

NCT07197034 is registered in ClinicalTrials.gov with Aardvark Therapeutics, Inc. as lead sponsor.

NCT NCT07197034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07197034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Open-Label Extension Study to Assess the Safety and Efficacy of ARD-101 in Patients With Prader-Willi Syndrome
Lead sponsor
Aardvark Therapeutics, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
July 23, 2024
Completion date
April 15, 2026
Enrollment
19 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

hyperphagia, hyperphagia in prader-willi syndrome, prader-willi syndrome